Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRIT-HF spironolactone in HFmrEF/HFpEF
NL-OMON54576Phase 3Terminated
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of spironolactone in heart failure with mid-range ejection fraction (HFmrEF), heart failure with preserved ejection fraction (HFpEF), sponsored by Charité – Universitätsmedizin Berlin. Started Jul 2020; status: terminated.
02
Drugs
spironolactone
03
Conditions
heart failure with mid-range ejection fraction (HFmrEF)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NL-OMON54576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54576.